Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.KaloBios Pharmaceuticals has entered into a research and commercial agreement with BioWa and Lonza to use their POTELLIGENT CHOK1SV cell line for the development and production of its humaneered antibodies.
Subscribe to our email newsletter
POTELLIGENT CHOK1SV is a new host cell line for manufacturing recombinant antibodies.
It combines the power of BioWa’s engineered glycosylation POTELLIGENT Technology with the advantages of Lonza’s proprietary GS Gene Expression System, which includes the cell line CHOK1SV.
BioWa said POTELLIGENT Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics.
Switzerland-based Lonza, a supplier to the pharmaceutical, healthcare and life science industries, is specialized in cell-based research, endotoxin detection and cell therapy manufacturing.
BioWa, a wholly owned subsidiary of Japan-based Kyowa Hakko Kirin Co, is the exclusive worldwide licensor of the AccretaMab platform.
The AccretaMab platform consists of POTELLIGENT and COMPLEGENT Technologies, creating a superior antibody molecule with enhanced ADCC and CDC activities.